Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy
| Autor: | Seema Patel, Coy D. Heldermon, Mathew Sebastian, Lisa Beth Spiryda, Hunter S. Futch, Chu J. Hsiao, Anne-Marie Carpenter, Mesfin Gobena, Mark L. Brantly, Leanne Dumeny, Divya S. Katikaneni, Robert S. Eisinger, Joel Cohen, Lei Jin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Adolescent Pneumococcal Infections Pneumococcal Vaccines 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Genotype medicine Humans Genetic variation Obesity Infectious disease Vaccines Attenuated vaccine business.industry Membrane Proteins General Medicine medicine.disease Antibodies Bacterial Fold change Vaccination Bacterial vaccine 030104 developmental biology Pneumococcal vaccine 030220 oncology & carcinogenesis Pneumococcal pneumonia Female Clinical Medicine business Bacterial vaccines |
| Zdroj: | JCI Insight |
| ISSN: | 2379-3708 |
| Popis: | BACKGROUND Obesity has been associated with attenuated vaccine responses and an increased risk of contracting pneumococcal pneumonia, but no study to our knowledge has assessed the impact of obesity and genetics on 23-valent pneumococcal vaccine (PPSV23) efficacy. We assessed the relationship of obesity (primary analysis) and stimulator of interferon genes (STING1) genotype (secondary analysis) on PPSV23 efficacy. METHODS Nonobese (BMI 22–25 kg/m2) and obese participants (BMI ≥30 kg/m2) were given a single dose of PPSV23. Blood was drawn immediately prior to and 4–6 weeks after vaccination. Serum samples were used to assess PPSV23-specific antibodies. STING1 genotypes were identified using PCR on DNA extracted from peripheral blood samples. RESULTS Forty-six participants were categorized as nonobese (n = 23; 56.5% women; mean BMI 23.3 kg/m2) or obese (n = 23; 65.2% women; mean BMI 36.3 kg/m2). Obese participants had an elevated fold change in vaccine-specific responses compared with nonobese participants (P < 0.0001). The WT STING1 group (R232/R232) had a significantly higher PPSV23 response than individuals with a single copy of HAQ-STING1 regardless of BMI (P = 0.0025). When WT was assessed alone, obese participants had a higher fold serotype-specific response compared with nonobese participants (P < 0.0001), but no difference was observed between obese and nonobese individuals with 1 HAQ allele (P = 0.693). CONCLUSIONS These observations demonstrate a positive association between obesity and PPSV23 efficacy specifically in participants with the WT STING1 genotype. TRIAL REGISTRATION ClinicalTrials.gov NCT02471014. FUNDING This research was supported by the NIH and the University of Florida MD-PhD Training Program. Obesity and a WT STING1 genotype are positively associated with efficacy of the 23-valent pneumococcal vaccine in a small cohort of subjects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|